Reid Waldman
CEO & Director
Thank you, everyone, for coming. This should be a lot of fun this afternoon. I’m Reid Waldman, Co-Founder and CEO of Veradermics. And today, we have really 3 topics that we’re going to address. One, we’re going to do a brief rehash of favorable topline data from Study 302, a Phase II/III registration-directed trial for male pattern hair loss. Two, we are going to briefly review market insights that were disclosed last week at Jefferies during our presentation. And then finally, we’re going to do a deep dive on female pattern hair loss ahead of upcoming data readouts.
I think all of you are familiar with our disclaimer related to forward-looking statements. Please read this in your own time. But today, we’re talking about pattern hair loss or androgenetic alopecia and as I think you all know, this is something that transcends being aesthetic. It’s deeply personal. It’s deeply psychological, it’s essentially universal affecting 80 million Americans, that makes this the single most prevalent chronic dermatologic condition in America, 10x more prevalent than psoriasis, 2x more prevalent than eczema and psoriasis combined. And despite this high prevalence, this is a market that is deeply dissatisfied. Only 9% of current treatment seekers are satisfied with their hair loss treatment. And nearly half of all patients are actively seeking a new treatment.
And that should come as no surprise given that today’s treatments are slow, they’re inconsistent, when they do work, they primarily deliver slight regrowth. And even with that lackluster efficacy profile, patients are forced to choose between tolerability issues like erectile dysfunction or decreased libido, or inconvenient and messy topical administration twice daily for the
